Related references
Note: Only part of the references are listed.Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols
A. Abendroth et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics
Kathleen A. Cronin et al.
CANCER (2018)
2-Aminopyridine-Based Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4) Inhibitors: Assessment of Mechanism-Based Safety
Robert L. Dow et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)
Lilian Schwarz et al.
BMC CANCER (2018)
The Regulation of JNK Signaling Pathways in Cell Death through the Interplay with Mitochondrial SAB and Upstream Post-Translational Effects
Sanda Win et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Licochalcone A Inhibits the Proliferation of Human Lung Cancer Cell Lines A549 and H460 by Inducing G2/M Cell Cycle Arrest and ER Stress
Chenyu Qiu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Sophoridine induces apoptosis and S phase arrest via ROS-dependent JNK and ERK activation in human pancreatic cancer cells
Zihang Xu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)
Pancreatic Adenocarcinoma, Version 2.2017
Margaret A. Tempero et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Targeting TAO Kinases Using a New Inhibitor Compound Delays Mitosis and Induces Mitotic Cell Death in Centrosome Amplified Breast Cancer Cells
Chuay-Yeng Koo et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Salmon provides fast and bias-aware quantification of transcript expression
Rob Patro et al.
NATURE METHODS (2017)
Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia A Population-based Retrospective Study
Maria Yi Ho et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2017)
c-Jun N-terminal kinase in pancreatic tumor stroma augments tumor development in mice
Takeshi Sato et al.
CANCER SCIENCE (2017)
Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer
Tetsuhito Muranaka et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2017)
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma
Andrew J. Aguirre et al.
CANCER CELL (2017)
Targeted Covalent Inhibitors for Drug Design
Thomas A. Baillie
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
Mustafa Suker et al.
LANCET ONCOLOGY (2016)
Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts
Matthew B. Lipner et al.
PLOS ONE (2016)
Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma
James D. Byrne et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
JNK1/2 expression and modulation of STAT3 signaling in oral cancer
Ioannis Gkouveris et al.
ONCOLOGY LETTERS (2016)
JNK pathway inhibition selectively primes pancreatic cancer stem cells to TRAIL-induced apoptosis without affecting the physiology of normal tissue resident stem cells
Alejandro Recio-Boiles et al.
ONCOTARGET (2016)
JNK Phosphorylates SIRT6 to Stimulate DNA Double-Strand Break Repair in Response to Oxidative Stress by Recruiting PARP1 to DNA Breaks
Michael Van Meter et al.
CELL REPORTS (2016)
Organoid Models of Human and Mouse Ductal Pancreatic Cancer
Sylvia F. Boj et al.
CELL (2015)
Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma
Richard A. Moffitt et al.
NATURE GENETICS (2015)
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
Hui Gao et al.
NATURE MEDICINE (2015)
Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone
Gaurab Chakrabarti et al.
SCIENTIFIC REPORTS (2015)
Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains
Timothy J. Stuhlmiller et al.
CELL REPORTS (2015)
JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells
Shuhei Suzuki et al.
ONCOTARGET (2015)
Impaired JNK Signaling Cooperates with KrasG12D Expression to Accelerate Pancreatic Ductal Adenocarcinoma
Clare C. Davies et al.
CANCER RESEARCH (2014)
Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial
Helmut Oettle et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Recent studies of 5-fluorouracil resistance in pancreatic cancer
Wei-Bin Wang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Targeting the K-Ras - JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation
Masashi Okada et al.
ONCOTARGET (2014)
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Michael I. Love et al.
GENOME BIOLOGY (2014)
Therapeutic effect of c-Jun N-terminal kinase inhibition on pancreatic cancer
Ryota Takahashi et al.
CANCER SCIENCE (2013)
Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial
Sophie Gourgou-Bourgade et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
miRNA-141, Downregulated in Pancreatic Cancer, Inhibits Cell Proliferation and Invasion by Directly Targeting MAP4K4
Gang Zhao et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
James S. Duncan et al.
CELL (2012)
Discovery of Potent and Selective Covalent Inhibitors of JNK
Tinghu Zhang et al.
CHEMISTRY & BIOLOGY (2012)
Development of JNK2-Selective Peptide Inhibitors That Inhibit Breast Cancer Cell Migration
Tamer S. Kaoud et al.
ACS CHEMICAL BIOLOGY (2011)
Molecular signatures database (MSigDB) 3.0
Arthur Liberzon et al.
BIOINFORMATICS (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Cross-talk between the p38α and JNK MAPK Pathways Mediated by MAP Kinase Phosphatase-1 Determines Cellular Sensitivity to UV Radiation
Christopher J. Staples et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
SP600125 suppresses Cdk1 and induces endoreplication directly from G2 phase, independent of JNK inhibition
J. A. Kim et al.
ONCOGENE (2010)
Gene ontology analysis for RNA-seq: accounting for selection bias
Matthew D. Young et al.
GENOME BIOLOGY (2010)
A selective small-molecule inhibitor of c-Jun N-terminal kinase 1
Ke Yao et al.
FEBS LETTERS (2009)
Expression of MAP4K4 Is Associated with Worse Prognosis in Patients with Stage II Pancreatic Ductal Adenocarcinoma
John J. Liang et al.
CLINICAL CANCER RESEARCH (2008)
Transcription factors control invasion: AP-1 the first among equals
B. W. Ozanne et al.
ONCOGENE (2007)
Second-line chemotherapy in advanced pancreatic Carcinoma: a multicenter survey of the gruppo oncologico italia meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice
V. Gebbia et al.
ANNALS OF ONCOLOGY (2007)
Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases
Marie A. Bogoyevitch et al.
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS (2006)
Osmotic stress activates the TAK1-JNK pathway while blocking TAK1-mediated NF-κB activation -: TAO2 regulates TAK1 pathways
Wei-Chun HuangFu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Prostate-derived sterile 20-like kinase 2 (PSK2) regulates apoptotic morphology via C-jun N-terminal kinase and Rho kinase-1
C Zihni et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
Ting-Chao Chou
PHARMACOLOGICAL REVIEWS (2006)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Inhibition of c-jun-N-terminal-kinase sensitizes tumor cells to CD95-induced apoptosis and induces G2/M CO cycle arrest
C Kuntzen et al.
CANCER RESEARCH (2005)
The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair
J Hayakawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
The specificities of protein kinase inhibitors: an update
J Bain et al.
BIOCHEMICAL JOURNAL (2003)
AP-1 in cell proliferation and survival
E Shaulian et al.
ONCOGENE (2001)
Signal transduction by the JNK group of MAP kinases
RJ Davis
CELL (2000)
Share Paper
